Kenneth Pacer, MD
Psychiatry · Kent, OHNPI 1033237300
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $119,261 of the $132,602 with a category attached, or 89.9%. 14 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 56.4% of the total. Among psychiatry clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $480.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$75K
- Supernus Pharmaceuticals, Inc.$49K
- Ironshore Pharmaceuticals Inc.$7K
- Corium, LLC$330
- E.r. Squibb & Sons, L.L.C.$179
- Johnson & Johnson$139
- plus $203 from 8 others
What the payments were for
- Speaking & faculty fees$119,26190%
- Travel & lodging$7,5816%
- Food & beverage$5,7174%
- Education$370%
- Gifts$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 103 | $74,773 |
| Supernus Pharmaceuticals, Inc. | 107 | $49,478 |
| Ironshore Pharmaceuticals Inc. | 32 | $7,500 |
| Corium, LLC | 13 | $330 |
| E.r. Squibb & Sons, L.L.C. | 5 | $179 |
| Johnson & Johnson | 5 | $139 |
| Neurocrine Biosciences, Inc. | 1 | $87 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $25 |
| Shire North American Group Inc | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Validus Pharmaceuticals LLC | 4 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$72,957
- QELBREE$45,690
- ABILIFY ASIMTUFII$44,091
- Jornay PM 20mg capsules (Bottle of 100)$6,806
- COBENFY$119
- Azstarys$114
How this compares
$132,602 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 45 | $127,379 |
| VraylarCariprazine Hcl | 49 | $67,464 |
| Invega SustennaPaliperidone Palmitate | 21 | $61,510 |
| TrintellixVortioxetine Hydrobromide | 33 | $25,719 |
| VyvanseLisdexamfetamine Dimesylate | 29 | $11,565 |
| IntunivGuanfacine Hcl | 28 | $7,389 |
| Lisdexamfetamine Dimesylate | 27 | $7,112 |
| Clozapine | 73 | $6,211 |
| BelsomraSuvorexant | 12 | $5,548 |
| AzstarysSerdexmethylphen/Dexmethylphen | 13 | $5,066 |
| Guanfacine Hcl ErGuanfacine Hcl | 61 | $4,659 |
| RisperdalRisperidone | 21 | $4,482 |
| Aripiprazole | 23 | $4,438 |
| Methylphenidate ErMethylphenidate Hcl | 43 | $2,709 |
| DepakoteDivalproex Sodium | 11 | $2,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $74,773 | $127,37945 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal | $139 | $65,99242 claims |
| Shire North American Group IncIntuniv | $16 | $7,38928 claims |
| Corium, LLCAzstarys | $330 | $5,06613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Kent
- Henry NasrallahCincinnati$3.8M
- Fred RomeoColumbus$2.3M
- Amita PatelDayton$2.1M
- Pradeep ManudhaneCanton$1.5M
- Michael SaribalasColumbus$1.2M
- Kevin WareColumbus$1.1M
- Binit ShahCleveland$913K
- Paul KeckCincinnati$739K
- Ali MelhemSteubenville$681K
- Tracey SkaleCincinnati$674K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.